Medicines Discovery Catapult Limited’s (MDC) Annual Report for the year ended 31 March 2023 is now published.
MDC ends the financial year 2022/23 having either met or exceeded its five-year grant funding targets. It has continued to transform great UK science for the sector into better treatments through partnership. It has developed pioneering, impactful R&D coalitions across biotech, academia, technology companies, charities, and global pharma.
During its first five years, MDC has developed and scaled rapidly, becoming a key pillar of the UK R&D landscape. MDC’s first core grant has already leveraged over £600m in private sector investment funding into SMEs, delivered over £67m in grant income, and partnered on over 230 R&D projects.
The report highlights some significant MDC milestones over the past year, including:
- Reaching pivotal milestones for its national industry-guided R&D coalitions in psychiatry and ageing, initiating further collaborative programmes
- Beginning work on new national technology programmes in imaging and complex medicines
- Providing new support for SMEs and start-ups through accelerator programmes
- Delivering a school engagement programme between MDC and the Cheshire and Warrington Local Enterprise Partnership to support regional skills development and encourage the next generation to consider a future in science in the North West’s thriving life science sector
- Delivering over 97 engagement opportunities via exhibitions and scientific poster presentations, being asked to join expert panels, chair events, and lead speaker slots at key scientific conferences, and being recognised by industry peers through various awards
- Driving the national conversation, harnessing its expertise to produce an ongoing range of effective thought leadership initiatives to provide critical commentary and guidance for the sector
Professor Chris Molloy, CEO of Medicines Discovery Catapult, said:
“Over the next five years, MDC will do what today’s sector community is asking of us. Firstly, to enable it, with MDC’s established technologies in imaging, disease modelling, informatics, and national coalitions. Secondly, to enhance it by using our biomarker technologies to support early phase clinical development – a critical value driver and route to investment for biotech. Thirdly, to help expand the sector, using MDC’s commercial skills, network, and resources to help high-risk assets safely reach the wider biotech investment community.
“MDC remains focused on its purpose to transform great UK science into better treatments through partnership: a team approach that translates the best of UK science into the best new treatments for the benefit of patients around the world and a thriving biotech sector at home.
“With our talented team at the helm, we begin our next cycle with momentum, revenues for reinvestment and a realisable goal to double MDC’s sector impact.”